Cysview Kit is a drug owned by Photocure Asa. It is protected by 7 US drug patents filed from 2013 to 2022. Out of these, 3 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 04, 2038. Details of Cysview Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11235168 | Method of photodynamic therapy (PDT) for bladder cancer |
Jan, 2038
(13 years from now) | Active |
| US11311620 | Neoadjuvant therapy for bladder cancer |
Dec, 2036
(12 years from now) | Active |
| US10556010 | Neoadjuvant therapy for bladder cancer |
Dec, 2036
(12 years from now) | Active |
| US7348361 | Solution for diagnosing or treating tissue pathologies |
Apr, 2019
(5 years ago) |
Expired
|
| US7530461 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
Jan, 2017
(7 years ago) |
Expired
|
| US6034267 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
Mar, 2016
(8 years ago) |
Expired
|
| US7247655 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
Mar, 2016
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cysview Kit's patents.
Latest Legal Activities on Cysview Kit's Patents
Given below is the list of recent legal activities going on the following patents of Cysview Kit.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 11 Aug, 2023 | US10556010 |
| Recordation of Patent Grant Mailed Critical | 26 Apr, 2022 | US11311620 |
| Patent Issue Date Used in PTA Calculation Critical | 26 Apr, 2022 | US11311620 |
| Email Notification Critical | 07 Apr, 2022 | US11311620 |
| Issue Notification Mailed Critical | 06 Apr, 2022 | US11311620 |
| Application Is Considered Ready for Issue Critical | 22 Mar, 2022 | US11311620 |
| Dispatch to FDC | 22 Mar, 2022 | US11311620 |
| Issue Fee Payment Received Critical | 21 Mar, 2022 | US11311620 |
| Issue Fee Payment Verified Critical | 21 Mar, 2022 | US11311620 |
| Recordation of Patent Grant Mailed Critical | 01 Feb, 2022 | US11235168 |
FDA has granted several exclusivities to Cysview Kit. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Cysview Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Cysview Kit.
Exclusivity Information
Cysview Kit holds 2 exclusivities. All of its exclusivities have expired in 2021. Details of Cysview Kit's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 28, 2013 |
| M(M-220) | Feb 15, 2021 |
US patents provide insights into the exclusivity only within the United States, but Cysview Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cysview Kit's family patents as well as insights into ongoing legal events on those patents.
Cysview Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cysview Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 04, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cysview Kit Generics:
There are no approved generic versions for Cysview Kit as of now.
About Cysview Kit
Cysview Kit is a drug owned by Photocure Asa. It is used for detection and diagnosis of bladder cancer using photodynamic cystoscopy. Cysview Kit uses Hexaminolevulinate Hydrochloride as an active ingredient. Cysview Kit was launched by Photocure Asa in 2010.
Approval Date:
Cysview Kit was approved by FDA for market use on 28 May, 2010.
Active Ingredient:
Cysview Kit uses Hexaminolevulinate Hydrochloride as the active ingredient. Check out other Drugs and Companies using Hexaminolevulinate Hydrochloride ingredient
Treatment:
Cysview Kit is used for detection and diagnosis of bladder cancer using photodynamic cystoscopy.
Dosage:
Cysview Kit is available in for solution form for intravesical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/VIAL | FOR SOLUTION | Prescription | INTRAVESICAL |